When compared to concomitant systemic AnxA5 protein and intratumoral E7 long peptide administration following cisplatin chemotherapy, systemic AnxA5-E7 fusion protein administration following cisplatin chemotherapy resulted in more effective antigen presentation by DCs in the tumor draining lymph node (Supplementary Fig. 9), which translated into better tumor control, prolonged mouse survival, and the generation of stronger tumor-specific CD8+ T cell responses (Supplementary Fig. 10). The gene discussed is ANXA5; the disease is neoplasm.